Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

The COVID-19 pandemic may be of particular concern for pregnant and breastfeeding women. We aimed to explore their beliefs about the coronavirus and COVID-19 vaccine willingness and to assess the impact of the pandemic on perinatal experiences and practices. A multinational, cross-sectional, web-based study was performed in six European countries between April and July 2020. The anonymous survey was promoted via social media. In total, 16,063 women participated (including 6661 pregnant and 9402 breastfeeding women). Most responses were collected from Belgium (44%), Norway (18%) and the Netherlands (16%), followed by Switzerland (11%), Ireland (10%) and the UK (3%). Despite differences between countries, COVID-19 vaccine hesitancy was identified among 40–50% of the respondents at the end of the first wave of the pandemic and was higher among pregnant women. Education level and employment status were associated with vaccine hesitancy. The first wave had an adverse impact on pregnancy experiences and disrupted access to health services and breastfeeding support for many women. In the future, access to health care and support should be maintained at all times. Evidence-based and tailored information on COVID-19 vaccines should also be provided to pregnant and breastfeeding women to avoid unfounded concerns about the vaccines and to support shared decision making in this population.

Details

Title
Vaccine Willingness and Impact of the COVID-19 Pandemic on Women’s Perinatal Experiences and Practices—A Multinational, Cross-Sectional Study Covering the First Wave of the Pandemic
Author
Ceulemans, Michael 1   VIAFID ORCID Logo  ; Foulon, Veerle 2 ; Panchaud, Alice 3 ; Winterfeld, Ursula 4 ; Pomar, Léo 5   VIAFID ORCID Logo  ; Lambelet, Valentine 5 ; Cleary, Brian 6 ; Fergal O’Shaughnessy 6   VIAFID ORCID Logo  ; Passier, Anneke 7 ; Jonathan Luke Richardson 8 ; Allegaert, Karel 9   VIAFID ORCID Logo  ; Nordeng, Hedvig 10   VIAFID ORCID Logo 

 Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium; [email protected] (V.F.); [email protected] (K.A.); Teratology Information Service, Pharmacovigilance Centre Lareb, 5237 MH ‘s Hertogenbosch, The Netherlands; [email protected] 
 Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium; [email protected] (V.F.); [email protected] (K.A.) 
 Service of Pharmacy, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland; [email protected]; Institute of Primary Health Care (BIHAM), University of Bern, 3012 Bern, Switzerland 
 Swiss Teratogen Information Service, Service de Pharmacologie Clinique, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland; [email protected] 
 Materno-Fetal and Obstetrics Research Unit, Lausanne University Hospital, 1011 Lausanne, Switzerland; [email protected] (L.P.); [email protected] (V.L.) 
 Rotunda Hospital, D01 P5W9 Dublin, Ireland; [email protected] (B.C.); [email protected] (F.O.); School of Pharmacy, Royal College of Surgeons Ireland, D02 VN51 Dublin, Ireland 
 Teratology Information Service, Pharmacovigilance Centre Lareb, 5237 MH ‘s Hertogenbosch, The Netherlands; [email protected] 
 UK Teratology Information Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE2 4AB, UK; [email protected] 
 Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium; [email protected] (V.F.); [email protected] (K.A.); Woman and Child, Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium; Department of Clinical Pharmacy, Erasmus MC Sophia Children’s Hospital, 3000 CA Rotterdam, The Netherlands 
10  Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, 0316 Oslo, Norway; [email protected]; Department of Child Health and Development, Norwegian Institute of Public Health, 0213 Oslo, Norway 
First page
3367
Publication year
2021
Publication date
2021
Publisher
MDPI AG
ISSN
1661-7827
e-ISSN
1660-4601
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2566043620
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.